- Home
- ERAS vs RYAN Comparison
ERAS vs RYAN Comparison
Compare ERAS & RYAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERAS | RYAN |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ERAS | RYAN |
|---|---|---|
| Price | $17.86 | $35.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $12.08 | ★ $49.81 |
| AVG Volume (30 Days) | ★ 5.0M | 1.7M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.45% |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,051,126,000.00 |
| Revenue This Year | N/A | $17.38 |
| Revenue Next Year | N/A | $13.17 |
| P/E Ratio | ★ N/A | $86.72 |
| Revenue Growth | N/A | ★ 21.28 |
| 52 Week Low | $1.06 | $31.50 |
| 52 Week High | $18.20 | $73.46 |
Technical Indicators
Market Signals| Indicator | ERAS | RYAN |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 50.48 |
| Support Level | $1.72 | $31.50 |
| Resistance Level | $18.20 | $40.44 |
| Average True Range (ATR) | 1.30 | 1.33 |
| MACD | 0.01 | 0.60 |
| Stochastic Oscillator | 88.45 | 88.49 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About RYAN Ryan Specialty Holdings Inc.
Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.